Fibrinogen Products (RiaSTAP®, Fibryga®)

RiaSTAP is covered only for treatment of acute bleeding in congenital fibrinogen deficiency (not for acquired deficiency), while Fibryga is covered for fibrinogen supplementation in bleeding patients with acquired fibrinogen deficiency and for treatment of acute bleeding in congenital fibrinogen deficiency; prophylactic/non‑bleeding indications are not covered. Coverage requires hematology prescribing/consultation, IV administration, adherence to product‑specific dosing and age/weight adjustments (use when fibrinogen level known: RiaSTAP 1.7 mg/dL per mg/kg; Fibryga 1.8 mg/dL per mg/kg ≥12 years and 1.4 mg/dL per mg/kg <12 years; if level unknown default 70 mg/kg; Fibryga acquired dosing: adults 4 g, adolescents ≥12 yrs 50 mg/kg, children <12 yrs 70 mg/kg), documentation of diagnosis/fibrinogen level/weight/age, and is limited to a 1‑month approval plus applicable safety criteria.

"Medication must be prescribed by or in consultation with a hematologist."